Broadcast Date: 
  • Time: 

The relevance of mRNA as a therapeutic strategy has gained prominence in recent years. Its success is primarily because of mRNA’s stability and translation efficiency due to sequence optimization and regulation in modification, the ability to target specific cells with sufficient production of proteins of interest without cellular amplification, and its functionality in the cytoplasm negating the risk of host genome integration. However, mRNA’s effectiveness can be compromised by degradation and reduced cellular uptake due to its large size and anionic charge. Using ionizable lipid nanoparticles (LNPs) addresses these issues by facilitating endosomal escape, stabilizing the nucleic acid cargo, and protecting it from nuclease degradation. With the success of the COVID-19 mRNA-based vaccines from Pfizer and Moderna, the demand for scaled-up production of mRNA-LNPs is rapidly growing.  

In this webinar, our expert will discuss the strategies for scaling up mRNA-LNP production in which the encapsulation approach (e.g. Nano Assemblr® Ignite™, Blaze™, etc.), method of buffer exchange, and filtration all play a significant role. He will touch on salient parameters that need to be considered at each juncture of the production phase dependent on the scale to ensure a safe and efficacious mRNA-LNP.

A live Q&A session followed the presentation, offering a chance to pose questions to our expert panelist.

Midhun Ben Thomas
Midhun Ben Thomas, PhD
Senior Scientist